Investigational drug · Phase 2
SAT-3247
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy, Duchenne, DMD.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SAT-3247"
First trial start
2025
Aug 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAT-3247", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy
- Duchenne
- DMD
- Neuromuscular Diseases
- Muscular Dystrophies
- Duchenne Muscular Dystrophy (DMD)
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SAT-3247" as an intervention, largest first.
Satellos Bioscience, Inc.Industry
NCT06565208 · 77 participants · Start Aug 21, 2024 · Primary completion Apr 28, 2025
Drug: SAT-3247; matched placebo · For: Duchenne Muscular Dystrophy
Sites: Adelaide, Australia; Bayswater, Australia
- A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)Not yet recruiting
Satellos Bioscience, Inc.Industry
NCT07872306 · 51 participants (planned) · Start Dec 15, 2026 · Primary completion Dec 30, 2028
Drug: forazapadin; Placebo Comparator · For: Facioscapulohumeral Muscular Dystrophy (FSHD)
- Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsActive, not recruiting
Satellos Bioscience, Inc.Industry
NCT07287189 · 51 participants (planned) · Start Dec 8, 2025 · Primary completion Mar 31, 2027
Drug: SAT-3247; Placebo · For: Duchenne Muscular Dystrophy; Duchenne; DMD and 2 more
Sites: Los Angeles, California; Aurora, Colorado; Chicago, Illinois · 20 sites in all
Satellos Bioscience, Inc.Industry
NCT06867107 · 30 participants (planned) · Start Sep 25, 2025 · Primary completion Sep 30, 2027
Drug: SAT-3247 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Los Angeles, California; St Louis, Missouri; Columbus, Ohio · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Duchenne Muscular Dystrophy
- AOC 1044Phase 33 trials
Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44
- DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials
Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic
- SGT-003Phase 32 trials
Solid Biosciences Inc. · Duchenne Muscular Dystrophy, Advanced Solid Tumor
- SevasemtenPhase 24 trials
Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- WVE-N531Phase 22 trials
Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy
- NS-050NCNP-03Phase 21 trial
NS Pharma, Inc. · Duchenne Muscular Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.